{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:26:26Z","timestamp":1783193186717,"version":"3.54.6"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the impact of bladder neck involvement (BNI) on oncological outcomes in non\u2010muscle\u2010invasive bladder cancer (NMIBC) and compare outcomes between Bacillus Calmette\u2010Gu\u00e9rin (BCG) and gemcitabine\/docetaxel (Gem\/Doce) intravesical therapies in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We analysed consecutive patients with NMIBC who underwent transurethral resection of bladder tumour (TURBT) and received BCG or Gem\/Doce from 2013 to 2023. BNI was defined as tumour presence at the bladder neck during TURBT. Recurrence\u2010free survival (RFS) and progression\u2010free survival (PFS) were assessed using Kaplan\u2013Meier and Cox regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 474 patients, 58 (12%) had BNI. The median (interquartile range) follow\u2010up time was 34\u2009(12\u201358)\u2009months. The 2\u2010year RFS was lower in the BNI group for any\u2010grade (41% vs 57%, log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) and high\u2010grade recurrence (56% vs 68%, log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). BNI independently predicted worse any\u2010grade RFS (hazard ratio [HR] 1.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), high\u2010grade RFS (HR 1.68,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), and PFS (HR 2.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). While BCG and Gem\/Doce had comparable 2\u2010year high\u2010grade RFS (59% vs 53%, log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.31) and PFS (88% vs 68%, log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07), the multivariable analysis revealed significantly increased risk of any\u2010grade recurrence (HR 1.75,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and progression (HR 2.72,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Maintenance therapy improved high\u2010grade RFS (HR 0.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and PFS (HR 0.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Limitations include retrospective design and single\u2010institution data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bladder neck involvement is an independent predictor of worse outcomes in NMIBC. While unadjusted outcomes were similar, multivariable analysis showed higher recurrence and progression risk with Gem\/Doce. Recognising BNI as a high\u2010risk factor may refine risk stratification and treatment decisions. Further studies are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16827","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:24:39Z","timestamp":1750033479000},"page":"1028-1036","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bladder neck involvement in non\u2010muscle\u2010invasive bladder cancer: risk implications and outcomes of BCG\u00a0vs gemcitabine\/docetaxel"],"prefix":"10.1111","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-6058","authenticated-orcid":false,"given":"Ahmed","family":"Eraky","sequence":"first","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7145","authenticated-orcid":false,"given":"Reuben","family":"Ben\u2010David","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-808X","authenticated-orcid":false,"given":"Brenda","family":"Hug","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9525-2600","authenticated-orcid":false,"given":"Kaushik P.","family":"Kolanukuduru","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-0486","authenticated-orcid":false,"given":"Neeraja","family":"Tillu","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-4697","authenticated-orcid":false,"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[{"name":"Department of Urology Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.08.018"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10462.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.107"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.09.021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.09.035"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3180588283"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0185(19990301)254:3<375::AID-AR8>3.0.CO;2-R"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42047-024-00151-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_2_9_11_1","article-title":"Clinical Spectrum of complications induced by intravesical immunotherapy of bacillus Calmette\u2010Gu\u00e9rin for bladder cancer","author":"Liu Y","year":"2019","journal-title":"J Oncol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9999-4"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.04.001"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04992-5"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.06.006"},{"key":"e_1_2_9_16_1","article-title":"Comparative effectiveness of bacillus Calmette\u2010Gu\u00e9rin and sequential intravesical gemcitabine and docetaxel for treatment\u2010na\u00efve intermediate\u2010risk non\u2010muscle\u2010invasive bladder cancer","author":"Kolanukuduru KP","year":"2024","journal-title":"Eur Urol Focus"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03104-9"},{"key":"e_1_2_9_19_1","article-title":"Differential response of low\u2010 and high\u2010grade intermediate\u2010risk non\u2010muscle\u2010invasive bladder cancer to bacillus Calmette\u2010Gu\u00e9rin and gemcitabine\u2010docetaxel therapy","volume":"43","author":"Eraky A","year":"2025","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4219"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.01.006"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15136"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.005"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9589-6"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070043"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15552"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2908295"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:18:02Z","timestamp":1767975482000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/bju.16827"],"URL":"https:\/\/doi.org\/10.1111\/bju.16827","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"2025-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}